tissue plasminogen activator
Although the serine protease, tissue plasminogen activator (tPA), is approved by        the US Food and Drug Administration for therapy to combat focal cerebral       infarction, the basic concept of thrombolytic tPA therapy for stroke was       challenged by recent studies that used genetically manipulated tPA-deficient       (tPA-/-) mice, which suggested that tPA mediates ischemic neuronal damage.
Although the serine protease,  @SUBJECT$  (tPA), is approved by        the US Food and Drug Administration for therapy to  @PREDICAT$  focal  @OBJECT$ , the basic concept of thrombolytic tPA therapy for stroke was       challenged by recent studies that used genetically manipulated tPA-deficient       (tPA-/-) mice, which suggested that tPA mediates ischemic neuronal damage.